Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance - AASLD | Cliniscan
Cliniscan
Solutions
Tarifs
Ressources
Se connecter
Essayer gratuitement
Cliniscan
Retour aux recommandations
AASLD
2024
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance
Document
Analyser ce document
